Phase 4
N=60
Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function
Cerebral Arterial Aneurysm
Bottom Line
View on ClinicalTrials.gov: NCT02691416 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcome: Primary: Evidences of Clinically Definite Oxidative Stress Confirmed by ELISA Kit — 72.87; 74.02; 67.10; 65.91 U/ml
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- propofol postconditioning (Drug); sevoflurane (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- The Third Central Clinical College of Tianjin Medical University
- Primary completion
- Dec 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evidences of Clinically Definite Oxidative Stress Confirmed by ELISA Kit |
72.87; 74.02; 67.10; 65.91; 66.74; 51.58 | — |
| PRIMARY Evidences of Clinically Definite Oxidative Stress Confirmed by ELISA |
1.15; 1.18; 1.19; 1.22; 1.54; 1.70 | — |
| PRIMARY Evidences of Clinically Definite Oxidative Stress:Micronuclei |
185.83; 186.40; 194.57; 195.73; 230.77; 375.87 | — |
| PRIMARY Evidences of Clinically Definite Oxidative Stress Confirmed by High Performance Liquid Chromatography |
12.67; 12.22; 6.13; 6.12; 6.71; 5.91 | — |
| PRIMARY Evidences of Clinically Definite Oxidative Stress: Nuclear Buds |
50.40; 53.93; 54.33; 57.43; 61.10; 62.87 | — |
| PRIMARY Evidences of Clinically Definite Oxidative Stress: Nucleoplasmic Bridges |
66.50; 68.73; 78.77; 80.80; 88.40; 96.23 | — |
| SECONDARY Mini Mental State Examination (MMSE) |
27.63; 27.23; 23.40; 17.73; 24.43; 20.33 | — |
| SECONDARY Montreal Cognitive Assessment (MoCA) |
20.43; 19.87; 21.53; 19.20; 22.53; 20.80 | — |
Summary
The purpose of this study was to evaluate differences between propofol postconditioning and sevoflurane anesthesia in the intracranial aneurysm surgery about antioxidant effect.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis intracranial aneurysm surgery ,
- American Society of Anesthesiologists (ASA)Ⅰ-Ⅱ.
Exclusion Criteria
- severe hepatic and renal dysfunction
- coagulation disorder
- taking antioxidant perioperative period
Data sourced from ClinicalTrials.gov (NCT02691416). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.